Skip to content
Home/Companies/Biotech/Amyl Therapeutics

Amyl Therapeutics

Biotech·Europe·Active·5yr hold
Entry
2021
Hold
5yr
Status
Active

Who owns Amyl Therapeutics?

Amyl Therapeutics is a Biotech company based in Europe, currently owned by Merieux Equity Partners since 2021.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Merieux Equity Partners
Investor
Merieux Equity Partners
Mérieux Innovation 1 · 2014 · VC

Key facts

HQEurope
SectorBiotech
StatusActive

More from Mérieux Innovation 1

Other portfolio companies in the same fund.

Broken String Biosciences
Broken String Biosciences
Active
BiotechUK· 2023
InnoSyn
InnoSyn
Active
PharmaNetherlands· 2023
LabQuality
LabQuality
Exited 2025
HealthcareFrance· 2023
to Aurevia
Cairdac
Cairdac
Active
MedTechFrance· 2022
Mablink Bioscience
Exited 2023
BiotechFrance· 2022
to Eli Lilly and Company
SeqOne Genomics
SeqOne Genomics
Active
BiotechFrance· 2022

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Amyl Therapeutics?

Amyl Therapeutics is currently owned by Merieux Equity Partners, through Mérieux Innovation 1, since 2021.

When did Merieux Equity Partners acquire Amyl Therapeutics?

Merieux Equity Partners acquired Amyl Therapeutics in 2021.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue